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Abstract Recent research suggests a role for ghrelin in
the modulation of inflammatory disorders. However, the
type of ghrelin receptor (GHS-R) involved in both the anti-
inflammatory and anti-hyperalgesic actions of ghrelin
remains to be characterized. In this study, we examined
whether the inhibitory effect of ghrelin in the development
of hyperalgesia and edema induced by intraplantar carra-
geenan administration depends on an interaction with
GHS-R1a. Both central (1 nmol/rat, i.c.v.) and peripheral
(40 nmol/kg, i.p.) administration of the selective GHS-R1a
agonist EP1572 had no effect on carrageenan-induced
hyperalgesia measured by Randall–Selitto test and paw
edema. Furthermore, pre-treatment with the selective GHS-
R1a antagonist, D-lys3-GHRP-6 (3 nmol/rat, i.c.v.) failed to
prevent the anti-hyperalgesic and anti-inflammatory effects
exerted by central ghrelin administration (1 nmol/rat), thus
indicating that the type 1a GHS-R is not involved in these
peptide activities. Accordingly, both central (1 and 2 nmol/
rat, i.c.v.) and peripheral (40 and 80 nmol/kg, i.p.)
administration of desacyl-ghrelin (DAG), which did not
bind GHS-R1a, induced a significant reduction of the
hyperalgesic and edematous activities of carrageenan. In
conclusion, we have shown for the first time that DAG
shares with ghrelin an inhibitory role in the development of
hyperalgesia, as well as the paw edema induced by carra-
geenan and that a ghrelin receptor different from type 1a is
involved in the anti-inflammatory activities of the peptide.
Keywords Ghrelin receptors  Desacyl-ghrelin 
Hyperalgesia  Edema  Randall and Selitto
Introduction
In this second decade of ghrelin research, numerous studies
showed considerable complexity within the ghrelin/ghrelin
receptor axis and indicate that an exciting aspect of ghrelin
biology could be the identification of receptors subtypes
mediating the various functions of the ghrelin-family
peptides.
Ghrelin, the endogenous ligand for the growth hormone
secretagogue receptor (GHS-R), was discovered in 1999
(Kojima et al. 1999). Ghrelin derives from a 117 amino
acid pre-prohormone which is cleaved into a 94 amino acid
proghrelin peptide. This proghrelin peptide is further
cleaved and gives rise to the 28 amino acid ghrelin peptide.
Two major forms of 28 amino acid ghrelin have been
identified (Hosoda et al. 2000). The ghrelin peptide acyl-
ated at serine-3 by ghrelin-O-acyltransferase (GOAT)
(Gutierrez et al. 2008; Yang et al. 2008), usually referred as
ghrelin in the literature, and a non-acylated form (DAG)
which circulates at tenfold higher levels than ghrelin
(Holmes et al. 2009; Patterson et al. 2005).
In addition to its GH-releasing activity, ghrelin influences
a broad range of biological processes, such as food intake and
energy expenditure, cell proliferation, gastrointestinal, car-
diovascular, pancreatic, pulmonary and immune functions
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(Cummings 2006; Leite-Moreira and Soares 2007; Van der
Lely et al. 2004). The biological activities exerted by ghrelin
seem to be mediated by an interaction with specific receptors.
Two forms of GHS-Rs have been identified: the fully func-
tional type 1a (GHS-R1a) and the truncated splice variant
GHS-R1b (Muccioli et al. 2001). The physiological role of
GHS-R1b is not clear, even if in vitro studies have suggested
that GHS-R1b may act as a negative regulator of GHS-R1a,
thus reducing its constitutive activation (Leung et al. 2007).
The octanoylation is critical for the binding to the GHS-R1a
and in inducing GH secretion, food intake (Kojima and
Kangawa 2005) and inhibition of gastric acid secretion
(Sibilia et al. 2006b). In fact, DAG seems to be devoid of any
endocrine and gastrointestinal activities.
Interestingly, both ghrelin and DAG inhibit apoptosis of
cardiomyocytes and endothelial cells (Baldanzi et al.
2002), which do not express GHS-R1a suggesting the
existence of an alternative, functionally active binding site,
yet to be identified (Seim et al. 2011), which could mediate
some of the effects of both peptides.
Recently, a number of studies have focussed on the role
of ghrelin in the control of pain perception. This interest is
justified by the evidence that the expression of ghrelin was
found in various brain areas involved in the control of
nociception, such as the hypothalamus, the sensorimotor
area of the cortex, the midbrain and the spinal cord (Guan
et al. 1997; Hou et al. 2006; Vergnano et al. 2008; Zigman
et al. 2006). The expression of GHS-R mRNA in the brain
is in keeping with the widespread distribution of ghrelin
receptors. Ghrelin receptors, in fact, are expressed in the
hypothalamus, in the pons medulla oblongata, in the sub-
stantia nigra and dorsal and median raphe nuclei, regions
implicated in the control of pain transmission (Nakazato
et al. 2001; Zigman et al. 2006).
Supporting a role for ghrelin as a pain modulator is also
the reported interaction of the peptide with endogenous
opioid containing neurons in the hypothalamic arcuate
nucleus and endocannabinoid system known to exert a
modulatory role in the central and peripheral regulation of
pain perception (Bloom et al. 1978; Riediger et al. 2003;
Tucci et al. 2004).
It has been reported that ghrelin administered either
centrally or peripherally prevents the development of acute
hyperalgesia induced by intraplantar carrageenan injection
in the rat (Sibilia et al. 2006a), and that long-term treatment
with ghrelin attenuates chronic neuropathic pain (Guneli
et al. 2010). Furthermore, ghrelin has been shown to
modulate inhibitory transmission in deep mouse spinal
cord dorsal horn (Ferrini et al. 2009; Vergnano et al. 2008).
In addition to an anti-nociceptive activity, ghrelin seems
to be a potent anti-inflammatory mediator. Strengthening this
view are in vitro studies showing that ghrelin is able to inhibit
the expression of the pro-inflammatory cytokines IL-1b, IL-6
and TNFa by T-cell receptor-activated T cells, LPS-activated
monocytes and dendritic cells (Dixit et al. 2004, Taub 2007)
and to reduce pro-inflammatory responses and nuclear factor
jB activation in endothelial cells (Li et al. 2004).
In vivo studies have shown that ghrelin treatment
reduces the severity of experimental models of sepsis
(Dixit et al. 2004; Wu et al. 2005), colitis (Gonzalez-Rey
et al. 2006) and paw edema consequent to carrageenan
injection (Sibilia et al. 2006a). Plus, long-term treatment
with the synthetic GHS-R agonist, GHRP-2 attenuates
arthritis in a rat model (Granado et al. 2005).
Also, clinical trials support the possibility that ghrelin
administration may be beneficial for cachexic patients and for
patients with chronic inflammatory diseases (Ashitani et al.
2009; Laviano et al. 2010). Such findings outline the potential
therapeutic use of ghrelin in inflammatory disorders.
However, the type of ghrelin receptor involved in both
the anti-hyperalgesic and anti-inflammatory activities of
the peptide remains to be clarified. The aim of this study
was, therefore, to examine whether both the anti-hyperal-
gesic and anti-inflammatory activities of ghrelin depend on
an interaction with GHS-R1a.
For this purpose, we examined the effects of intracere-
broventricular (i.c.v.) or peripheral (i.p.) injection of the
GHS-R1a agonist, EP1572 (Broglio et al. 2002; Sibilia
et al. 2006b) on carrageenan-induced hyperalgesia and paw
edema and the reversibility of both the ghrelin anti-noci-
ceptive and anti-inflammatory activities by the specific
GHS-R1a antagonist D-lys3-GHRP-6 (Carreira et al. 2006;
Muccioli et al. 2007; Sibilia et al. 2006b).
Carrageenan is a sulfated polysaccharide extracted from
the seaweed Chondrus crispus. Carrageenan-induced hind
paw inflammation is a neutrophil-mediated acute inflam-
matory response with clinical symptoms peaking at 1 to
3 h after the intraplantar injection of carrageenan (Winter
et al. 1962). The carrageenan-inflamed hind paw also is
painful, and hyperalgesia can be reliably measured using
established behavioral pain assays such as Randall and
Selitto test (Randall and Selitto 1957).
On the basis of the results obtained, we examined the
effect of central or peripheral injection of DAG, which
does not bind the classic GHS-R1a (Bednarek et al. 2000;
Ghigo et al. 2005), on pain perception and paw edema by
using the same experimental model of acute inflammation.
Methods
Animals and surgery
Male Sprague–Dawley rats (125–150 g; Harlan Italy) were
used. Upon arrival, the rats were housed in single cages under
controlled illumination (12 h light/12 h darkness cycle),
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humidity (65%) and temperature (22 ± 2C) with free
access to water and laboratory chow pellets (Charles River).
For the i.c.v. administration of peptides, a polyethylene
cannula (PE10) was implanted into the left lateral ventricle
of the brain, 5 days before the experiment, as previously
described (Netti et al. 1984). At the end of the experiment
(after rats were euthanized with CO2), 5 ll of dye (0.5%
Evans blue) was injected through the cannula to confirm its
position in the ventricle.
All experiments were approved by the Italian Ministry
of Health and performed in accordance with the European
Directive 2010/63/EU.
Drugs
Ghrelin, DAG and EP1572 [Aib-DTrp-DgTrp-CHO] were
synthesized by conventional solid phase synthesis and
purified to at least 98% by HPLC by Neosystem (Strasburg,
France). D-Lys3-GHRP-6 was purchased from Bachem AG
(Budendorf, Switzerland). The peptides were dissolved in
saline immediately before the experiment and were injec-
ted in a volume of 5 ll/rat, i.c.v. or 2 ml/kg, i.p. carra-
geenan (0.1 ml of 1% solution in distilled water, Gianni,
Italy), which was injected into the right plantar hind paw
(i.pl.). In all experiments, an equal volume of saline was
used as control.
Carrageenan-induced hyperalgesia and edema
The nociceptive thresholds of the hind paw after mechan-
ical stimulation, according to the method of Randall and
Selitto (1957), were quantified with a Basile algesimeter
(Milan, Italy). Each rat was gently held with a hind paw
placed under a pressure pad. The force, in grams, applied to
the paw was increased at a constant rate until the rat
withdrew its paw. The pressure was immediately removed
and the force required to elicit the end-point response was
noted. A cutoff of 400 g was used. The rats were trained in
the nociceptive test daily for 2 days before the experiment.
This adaptation procedure produces a stable baseline paw
pressure threshold (PPT) (Taiwo et al. 1989).
Carrageenan-induced paw edema was measured by
water displacement plethysmography at selected times
after carrageenan injection by placing the paw up to the
tibio-tarsic articulation (marked with ink) into the chamber
of the plethysmometer (Basile, Milan, Italy). The dis-
placement volume (ml) was measured by a transducer.
Experimental procedures
On the day of the experiment, following baseline testing,
carrageenan (T0) was injected into the plantar region (i.pl.)
of the rat right hind paw. The GHS-R1a agonist, EP1572,
DAG and ghrelin were injected by the i.c.v route 5 min
before carrageenan. When peripherally administered,
EP1572 and DAG were injected 30 min before carra-
geenan. We used doses of EP1572 or DAG equimolar to
those of ghrelin previously reported to exert an anti-
inflammatory activity (Sibilia et al. 2006a).
To see whether the GHS-R1a antagonist, D-lys3-GHRP-6,
was able to interfere with the central anti-hyperalgesic and
anti-inflammatory effect of ghrelin, the compound was
injected i.c.v. 5 min before ghrelin (1 nmol/rat, i.c.v.) and
135 min from carrageenan. D-Lys3-GHRP-6 was adminis-
tered at a dose previously reported to abolish the inhibitory
effect of ghrelin on gastric acid secretion (Sibilia et al. 2006b).
In all cases, the nociceptive thresholds and the volume of
the inflamed paw were measured before (basal) and at 150,
210 and 270 min after carrageenan. The operator of the paw
tests was unaware of the treatments during the test period.
Statistical analysis
Statistical analysis was performed by a statistical package
(SigmaStat, vers. 3.1 Systat Software). All data are repor-
ted as the mean ± SEM. Data were analyzed by two-way
repeated measures analysis of variance (ANOVA, factors:
treatment and time) followed by Bonferroni t test. A
probability of P \ 0.05 was considered to be significant.
Results
Effects of central or peripheral administration
of the GHS-R1a agonist, EP1572, on carrageenan-
induced hyperalgesia and edema
As shown in Fig. 1a and b, i.pl. injection of carrageenan pro-
duced a significant reduction of PPT and an increase in paw
volume as compared with the pre-carrageenan values. Central
administration of 1 nmol/rat of the GHS-R1a agonist, EP1572,
had no significant effect on carrageenan-induced hyperalgesia
(Ftreatment = 0.241; Ftime = 38.25; P \ 0.001) and paw
edema (Ftreatment = 0.16; Ftime =271.65; P \ 0.001).
Similar results on carrageenan-induced hyperalgesia
(Ftreatment = 0.85; Ftime = 42.36; P \ 0.001) and paw
edema (Ftreatment = 0.094; Ftime = 607.43; P \ 0.001)
were obtained when EP1572 (40 nmol/kg, i.p.) was periph-
erally administered 30 min prior to carrageenan (Fig. 2a, b).
Effects of central administration of the GHS-R1a
antagonist, D-lys3-GHRP-6, on ghrelin-induced anti-
nociceptive and anti-inflammatory activities
As expected, central ghrelin administration (1 nmol/rat,
i.c.v.) caused a significant inhibition of carrageenan-
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induced hyperalgesia as compared with saline-treated rats,
which peaked at 150 min from carrageenan and lasted until
270 min. Central administration of the specific GHS-R1a
antagonist, D-lys3-GHRP-6 (3 nmol/rat, i.c.v.), had no
effect on the development of hyperalgesia induced by
carrageenan. When administered before ghrelin, D-lys3-
GHRP-6 not only did not affect the anti-hyperalgesic effect
of central ghrelin but significantly increased the anti-
hyperalgesic effect of ghrelin at 150 min from carrageenan
(Fig. 3a). Two-way ANOVA revealed significant main
effects of treatment (F = 29.85; P \ 0.001), time
(F = 21.57; P \ 0.001) and interaction between treatment
and time (F = 4.22; P \ 0.001).
D-Lys3-GHRP-6 had no effect on carrageenan-induced
paw edema and failed to remove the anti-inflammatory
action of ghrelin (Fig. 3b). In fact, the reduction of paw
edema in rats treated with D-lys3-GHRP-6 and ghrelin was
similar to that of ghrelin treated rats. Two-way ANOVA
revealed significant main effects of treatment (F = 7.29;
P = 0.001), time (F = 555.16; P \ 0.001) and interaction
between treatment and time (F = 2.53; P = 0.01).
To test the possibility that the ineffectiveness of D-lys3-
GHRP-6 could be due to its short duration of action, rats
were treated i.c.v. with D-lys3-GHRP-6 (3 nmol/rat, i.c.v.)
twice, before ghrelin injection (1 nmol/rat, i.c.v.) and
135 min after carrageenan administration (Fig. 4a, b). Also
in this case, D-lys3-GHRP-6 was not able to remove the
anti-hyperalgesic (Ftreatment = 7.4; P = 0.001; Ftime =
14.86; P \ 0.001; Ftreatment and time = 2.51; P = 0.01) and
anti-inflammatory (Ftreatment = 15.34; P \ 0.001; Ftime =
329.17; P \ 0.001; Ftreatment and time = 6.64; P \ 0.001)
effects of central ghrelin administration.
Effects of central or peripheral administration of DAG
on carrageenan-induced hyperalgesia and edema
To test the possibility that the anti-nociceptive activity of
ghrelin could be linked to an interaction with a receptor
Fig. 1 Effect of intracerebroventricular (i.c.v.) injection of EP1572
on hyperalgesia (a) and paw edema (b) induced by carrageenan.
EP1572 was administered 5 min before i.pl. carrageenan. Paw
pressure threshold and paw volume were measured prior to
carrageenan (basal) and at various times after carrageenan. Each
value is the mean ± SEM of 10–12 rats. **P \ 0.001 versus basal
Fig. 2 Effect of peripheral (i.p.) injection of EP1572 on hyperalgesia
(a) and paw edema (b) induced by carrageenan. EP1572 was
administered 30 min before i.pl. carrageenan. Paw pressure threshold
and paw volume were measured prior to carrageenan (basal) and at
various times after carrageenan. Each value is the mean ± SEM of
10–12 rats. **P \ 0.001 versus basal
1754 V. Sibilia et al.
123
different from GHS-R1a, we treated rats either i.c.v. or i.p.
with DAG, which is devoid of effects linked to GHS-R1a
activation (Kojima and Kangawa 2005; Seim et al. 2011).
Figure 5a shows that central DAG administration caused a
significant reduction in the hyperalgesia induced by car-
rageenan starting from 150 min after carrageenan
throughout the experimental period. The anti-nociceptive
effects observed at the doses of 1 and 2 nmol/rat were of
the same intensity. Two-way ANOVA revealed significant
main effects of treatment (F = 10.6; P \ 0.001), time
(F = 49.12; P \ 0.001) and interaction between treatment
and time (F = 4.13; P \ 0.01).
DAG anti-nociception was accompanied by an anti-
inflammatory activity. DAG at 1 and 2 nmol/rat induced a
long-lasting decrease of paw edema that reaches statistical
significance from carrageenan–saline-treated rats starting
from 210 and 150 min from carrageenan, respectively
(Fig. 5b). Two-way ANOVA revealed significant main
effects of treatment (F = 5.43; P \ 0.01), time (F =
721.22; P \ 0.001) and interaction between treatment and
time (F = 5.55; P \ 0.01).
Systemic DAG administration (40 and 80 nmol/kg, i.p)
induced a significant increase in PPT peaking at 270 min
from carrageenan, only at the higher dose used (Fig. 6a).
Two-way ANOVA revealed significant main effects of
treatment (F = 8.1; P \ 0.002) and time (F = 89.58;
P \ 0.001).
DAG at 80 nmol/kg i.p. induced a significant decrease
of paw edema compared with carrageenan–saline-treated
rats starting from 150 min from carrageenan throughout
the experimental period (Fig. 6b). Two-way ANOVA
revealed significant main effects of treatment (F = 5.23;
P \ 0.01), time (F = 533.41; P \ 0.001) and interaction
between treatment and time (F = 2.25; P = 0.05).
Fig. 3 Effect of pretreatment (5 min before) with D-lys3-GHRP-6 on
the inhibitory action of ghrelin on hyperalgesia (a) and paw edema
(b) induced by i.pl. carrageenan. Ghrelin was injected i.c.v. 5 min
before i.pl. carrageenan. Paw pressure threshold and paw volume
were measured prior to carrageenan (basal) and at various times after
carrageenan. Each value is the mean ± SEM of 12–14 rats.
**P \ 0.001 versus basal; ••P \ 0.01, •••P \ 0.001 versus saline;
#P \ 0.05 versus ghrelin
Fig. 4 Effect of intracerebroventricular (i.c.v.) injection of D-lys3-
GHRP-6 on the inhibitory action of ghrelin on hyperalgesia (a) and
paw edema (b) induced by i.pl. carrageenan. D-Lys3-GHRP-6 was
injected 5 min before ghrelin and 135 min after carrageenan. Ghrelin
was injected i.c.v. 5 min before i.pl. carrageenan. Paw pressure
threshold and paw volume were measured prior to carrageenan (basal)
and at various times after carrageenan. Each value is the mean ±
SEM of 6–8 rats. **P \ 0.001 versus basal; ••P \ 0.01, •••P \ 0.001
versus saline; #P \ 0.05 versus ghrelin
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Discussion
The present study was aimed to determine whether GHS-
R1a mediates the inhibitory effects of ghrelin on hyperal-
gesia and paw edema induced by carrageenan in the rat.
For this purpose, we used ghrelin, synthetic analogues
acting as GHS-R1a agonist (EP1572) or antagonist (D-lys3-
GHRP-6) and the natural ghrelin isoform, DAG which does
not bind GHS-R-1a (Muccioli et al. 2007).
The results obtained demonstrate that either central or
peripheral EP1572 administration did not reduce the
development of hyperalgesia induced by i.pl. carrageenan.
Furthermore, pre-treatment with the selective GHS-R1a
antagonist, D-lys3-GHRP-6 did not prevent the inhibitory
control of inflammatory pain elicited by central ghrelin
administration.
These observations raise the possibility that the anti-
nociceptive action of ghrelin could be independent of the
presently known ghrelin receptor GHS-R1a. Accordingly,
both central and peripheral DAG administration was
effective in preventing carrageenan-induced hyperalgesia.
It is possible that the anti-hyperalgesic effect of DAG
could be due to a modulatory action on the central pain
circuits activated by peripheral inflammation. Supporting
this view are the present data showing that a high dose of
peripherally administered DAG (80 nmol/kg) is required to
achieve an anti-hyperalgesic effect similar to the one
induced by central DAG injection (1 nmol/rat) and by
previous studies demonstrating that DAG is able to cross
the BBB and to increase c-Fos expression in the arcuate
nucleus and in the paraventricular nucleus of the hypo-
thalamus (Chen et al. 2005).
When we compared the anti-hyperalgesic effects of
ghrelin and DAG, we found that the intensity and pattern of
DAG response differ from those of ghrelin.
Ghrelin, in fact, centrally or peripherally administered
exerts a dose-dependent and long-lasting anti-nociceptive
Fig. 5 Effect of intracerebroventricular (i.c.v.) injection of desacyl-
ghrelin (DAG) on hyperalgesia (a) and paw edema (b) induced by
carrageenan. DAG was administered 5 min before i.pl. carrageenan.
Paw pressure threshold and paw volume were measured prior to
carrageenan (basal) and at various times after carrageenan. Each
value is the mean ± SEM of 10–12 rats. *P \ 0.05, **P \ 0.001
versus basal; •P \ 0.05, ••P \ 0.01, •••P \ 0.001 versus saline
Fig. 6 Effect of peripheral (i.p.) injection of desacyl-ghrelin (DAG)
on hyperalgesia (a) and paw edema (b) induced by carrageenan. DAG
was administered 30 min before i.pl. carrageenan. Paw pressure
threshold and paw volume were measured prior to carrageenan (basal)
and at various times after carrageenan. Each value is the mean ±
SEM of 10–12 rats. **P \ 0.001 versus basal; •P \ 0.05, ••P \ 0.01
versus saline
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activity that peaked at 150 min from carrageenan (Sibilia
et al. 2006a), whereas DAG, administered at doses equi-
molar to the ones previously used for ghrelin, elicits a less
marked anti-nociceptive activity that peaked at 270 min
from carrageenan.
The differences in the onset and the anti-hyperalgesic
activity between ghrelin and DAG could imply that DAG
must be acylated and converted into the active octanoylated
form by the recently identified enzyme GOAT (Gutierrez
et al. 2008; Yang et al. 2008). To understand the physio-
logical role of acylated ghrelin and the relevance of the
conversion of DAG into the acylated form in the control of
pain perception, further studies with GOAT knockout mice
or with the pharmacological GOAT antagonist, Go-CoA-
Tat (Barnett et al. 2010), will be required.
Alternatively, DAG could recognize, with lower affinity
than ghrelin, a common binding site different from GHS-
R1a involved in the modulation of pain perception. In this
context, binding studies have shown that DAG is able to
displace [125I]-Tyr4-ghrelin binding from cells which do
not express GHS-R1a (Muccioli et al. 2007).
The lack of the involvement of GHS-R1a in mediating
the anti-nociceptive action of ghrelin is supported by the
present results obtained with the selective GHS-R1a ago-
nist (EP1572), which has no effect on carrageenan-induced
hyperalgesia. It is unlikely that the lack of effect of
peripherally administered EP1572 could be due to its
pharmacokinetic profile, since we used a dose of EP1572
higher than those previously reported to be effective in
inhibiting gastric acid secretion in rats 3 h after pylorus
ligation (Sibilia et al. 2006b).
The anti-hyperalgesic action of ghrelin was not blocked
by pre-treatment with the specific GHS-R1a antagonist, D-
lys3-GHRP-6. It is worth noting that in rats pre-treated with
D-lys3-GHRP-6, ghrelin induced at 150 min from carra-
geenan, an increase in PPT was significantly higher than the
one detected in rats receiving ghrelin alone. Thus, it is pos-
sible that D-lys3-GHRP-6 by acting as an antagonist for GHS-
R1a could have shifted ghrelin binding to the receptor type
mainly involved in the control of pain perception.
At variance to our results, Vergnano et al. (2008) have
shown that ghrelin enhances inhibitory neurotransmission
in the mouse spinal cord dorsal horn mainly through an
interaction with GHS-R1a. However, the authors did not
rule out the existence of an unknown additional ghrelin
receptor different from the GHS-R1a mediating the anti-
nociceptive action of the peptide. In fact, D-lys3-GHRP-6
was not able to completely remove the ghrelin inhibitory
effect, and a subset of ghrelin responsive neurons showed
an increase in the frequency of spontaneous inhibitory
postsynaptic currents after DAG application.
It may well be possible that the varying results of these
studies could depend on the different experimental models
(in vitro vs. in vivo studies) or to the different animal
species used (mouse vs. rat). However, further in vivo
studies designed to examine the effects of intrathecal
ghrelin will be necessary to clarify the involvement of
spinal GHS-R1a in modulating spinal nociceptive
transmission.
It is unlikely that the GHS-R1a could be involved in the
central anti-inflammatory action of ghrelin, since we found
that central EP1572 injection has no effect on carrageenan-
induced edema and that pre-treatment with D-lys3-GHRP-6
failed to modify the central anti-edematous action of
ghrelin.
Support for an anti-inflammatory role for peripheral
GHS-R1a comes from several studies. In vitro studies have
shown that GHS-R1a is expressed on lymphocytes and that
administration of a GHS-R1a agonist decreases expression
of inflammatory cytokines by activated monocytes and T
cells (Dixit et al. 2004). Furthermore, long-term adminis-
tration of the synthetic GHS-R1a agonist, GHRP-2 has an
anti-inflammatory effect in arthritic rats (Granado et al.
2005).
The involvement of peripheral GHS-R1a in the inhibi-
tory role of ghrelin on the development of acute inflam-
mation induced by carrageenan seems to be ruled out. In
fact, neither intraplantar ghrelin injection (Sibilia et al.
2006a) nor peripheral administration of the GHS-R1a
agonist EP1572 was able to modify paw edema induced by
carrageenan. These discrepancies could be linked to dif-
ferences related to the rodent models of inflammation used
or to the dose and schedule of ghrelin/synthetic GHS
treatment.
Interestingly, we found that DAG shares with ghrelin a
central anti-inflammatory activity. However, also in this
case, DAG was less effective than ghrelin reaching the
maximal decrease in paw edema at a dose (2 nmol/rat)
higher than that previously shown for ghrelin (1 nmol/rat).
Recent in vitro studies have suggested that the scavenger
receptor CD36 could be involved in the anti-inflammatory
action of DAG. In fact, DAG is able to reduce the
b-amyloid activation of CD36 in mouse microglia cells
which results in increased release of reactive oxygen spe-
cies and inflammatory cytokines, whereas ghrelin was
inactive (Bulgarelli et al. 2009).
The possibility that CD36 could be involved in the in
vivo anti-inflammatory activity of DAG seems to be ruled
out, since hexarelin, a synthetic GHS which specifically
binds to CD36 (Muccioli et al. 2007) and shares with DAG
the ability to interfere with activation of CD36 in microglia
cells (Bulgarelli et al. 2009), has no significant effect both
on carrageenan-induced hyperalgesia and paw edema (data
not shown).
In conclusion, we have shown for the first time that
DAG shares with ghrelin an inhibitory role in the
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development of hyperalgesia, as well as the paw edema
induced by carrageenan and that a ghrelin receptor differ-
ent from 1a is involved in both the anti-inflammatory and
anti-hyperalgesic activities of the peptide. This assumption
is supported by previous studies indicating that DAG, did
not bind to GHS-R1a and by the present results showing
that the selective GHS-R1a agonist, EP1572, was ineffec-
tive in reducing the development of inflammation induced
by carrageenan. Furthermore, the GHS-R1a antagonist,
D-lys3-GHRP-6 did not alter both the anti-hyperalgesic and
anti-inflammatory action of ghrelin.
The identification of natural or synthetic ligands acting
with high specificity on this type of ghrelin receptor would
have perspective in terms of clinical application as anti-
inflammatory drugs.
Acknowledgments This work was supported by funds from FIRST
2009 to VS.
Conflict of interest The authors declare that there is no conflict of
interest that would prejudice the impartiality of this scientific work.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Ashitani J, Matsumoto N, Nakazato M (2009) Ghrelin and its
therapeutic potential for cachectic patients. Peptides 30:
1951–1956
Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini
A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N,
Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M,
Muccioli G, Ghigo E, Graziani A (2002) Ghrelin and des-acyl
ghrelin inhibit cell death in cardiomyocytes and endothelial cells
through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159:1029–1037
Barnett BP, Hwang Y, Taylor MS, Kirchner H, Pfluger PT, Bernard
V, Lin YY, Bowers EM, Mukherjee C, Song WJ, Longo PA,
Leahy DJ, Hussain MA, Tscho¨p MH, Boeke JD, Cole PA (2010)
Glucose and weight control in mice with a designed ghrelin
O-acyltransferase inhibitor. Science 330:1689–1692
Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva
MV, Warren VA, Howard AD, Van Der Ploeg LH, Heck JV
(2000) Structure-function studies on the new growth hormone-
releasing peptide, ghrelin: minimal sequence of ghrelin neces-
sary for activation of growth hormone secretagogue receptor 1a.
J Med Chem 43:4370–4376
Bloom F, Battenberg E, Rossier J, Ling N, Guillemin R (1978)
Neurons containing beta-endorphin in rat brain exist separately
from those containing enkephalin: immunocytochemical studies.
Proc Natl Acad Sci USA 75:1591–1595
Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghe`
C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D,
Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R
(2002) EP1572: a novel peptido-mimetic GH secretagogue with
potent and selective GH-releasing activity in man. J Endocrinol
Invest 25:RC26–RC28
Bulgarelli I, Tamiazzo L, Bresciani E, Rapetti D, Caporali S, Lattuada
D, Locatelli V, Torsello A (2009) Desacyl-ghrelin and synthetic
GH-secretagogues modulate the production of inflammatory
cytokines in mouse microglia cells stimulated by beta-amyloid
fibrils. J Neurosci Res 87:2718–2727
Carreira MC, Camin˜a JP, Dı´az-Rodrı´guez E, Alvear-Perez R,
Llorens-Cortes C, Casanueva FF (2006) Adenosine does not
bind to the growth hormone secretagogue receptor type-1a
(GHS-R1a). J Endocrinol 191:147–157
Chen CY, Inui A, Asakawa A, Fujino K, Kato I, Chen CC, Ueno N,
Fujimiya M (2005) Des-acyl ghrelin acts by CRF type 2
receptors to disrupt fasted stomach motility in conscious rats.
Gastroenterology 129:8–25
Cummings DE (2006) Ghrelin and the short- and long-term regulation
of appetite and body weight. Physiol Behav 89:71–84
Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK,
Palaniappan R, Lillard JW Jr, Taub DD (2004) Ghrelin inhibits
leptin- and activation-induced proinflammatory cytokine expres-
sion by human monocytes and T cells. J Clin Invest 114:57–66
Ferrini F, Salio C, Lossi L, Merighi A (2009) Ghrelin in central
neurons. Curr Neuropharmacol 7:37–49
Ghigo E, Broglio F, Arvat E, Maccario M, Papotti M, Muccioli G
(2005) Ghrelin: more than a natural GH secretagogue and/or an
orexigenic factor. Clin Endocrinol 62:1–17
Gonzalez-Rey E, Chorny A, Delgado M (2006) Therapeutic action of
ghrelin in a mouse model of colitis. Gastroenterology 130:
1707–1720
Granado M, Priego T, Martı´n AI, Villanu´a MA, Lo´pez-Caldero´n A
(2005) Ghrelin receptor agonist GHRP-2 prevents arthritis-
induced increase in E3 ubiquitin-ligating enzymes MuRF1 and
MAFbx gene expression in skeletal muscle. Am J Physiol
Endocrinol Metab 289:E1007–E1014
Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sir-
inathsinghji DJ, Smith RG, Van der Ploeg LH, Howard AD
(1997) Distribution of mRNA encoding the growth hormone
secretagogue receptor in brain and peripheral tissues. Brain Res
Mol Brain Res 48:23–29
Guneli E, Onal A, Ates M, Bagriyanik HA, Resmi H, Orhan CE,
Kolatan HE, Gumustekin M (2010) Effects of repeated admin-
istered ghrelin on chronic constriction injury of the sciatic nerve
in rats. Neurosci Lett 479:226–230
Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD,
Jin Z, Witcher DR, Luo S, Onyia JE, Hale JE (2008) Ghrelin
octanoylation mediated by an orphan lipid transferase. Proc Natl
Acad Sci USA 105:6320–6325
Holmes E, Davies I, Lowe G, Ranganath LR (2009) Circulating
ghrelin exists in both lipoprotein bound and free forms. Ann Clin
Biochem 46:514–516
Hosoda H, Kojima M, Matsuo H, Kangawa K (2000) Ghrelin and des-
acyl ghrelin: two major forms of rat ghrelin peptide in gastroin-
testinal tissue. Biochem Biophys Res Commun 279:909–913
Hou Z, Miao Y, Gao L, Pan H, Zhu S (2006) Ghrelin-containing
neuron in cerebral cortex and hypothalamus linked with the
DVC of brainstem in rat. Regul Pept 134:126–131
Kojima M, Kangawa K (2005) Ghrelin: structure and function.
Physiol Rev 85:495–522
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K
(1999) Ghrelin is a growth-hormone-releasing acylated peptide
from stomach. Nature 402:656–660
Laviano A, Krznaric Z, Sanchez-Lara K, Preziosa I, Cascino A, Rossi
Fanelli F (2010) Chronic renal failure, cachexia, and ghrelin. Int
J Pept (pii: 648045)
Leite-Moreira AF, Soares JB (2007) Physiological, pathological and
potential therapeutic roles of ghrelin. Drug Discov Today 12:
276–288
Leung PK, Chow KB, Lau PN, Chu KM, Chan CB, Cheng CH, Wise
H (2007) The truncated ghrelin receptor polypeptide (GHS-R1b)
1758 V. Sibilia et al.
123
acts as a dominant-negative mutant of the ghrelin receptor. Cell
Signal 19:1011–1022
Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL,
McCormick ML, Sigmund CD, Tang C, Weintraub NL (2004)
Ghrelin inhibits proinflammatory responses and nuclear factor-
kappaB activation in human endothelial cells. Circulation 109:
2221–2226
Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R (2001)
Binding of 125I-labeled ghrelin to membranes from human
hypothalamus and pituitary gland. J Endocrinol Invest 24:RC7–
RC9
Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E (2007)
Heterogeneity of ghrelin/growth hormone secretagogue recep-
tors. Toward the understanding of the molecular identity of novel
ghrelin/GHS receptors. Neuroendocrinology 86:147–164
Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa
K, Matsukura S (2001) A role for ghrelin in the central
regulation of feeding. Nature 409:194–198
Netti C, Bossa R, Galatulas I, Sibilia V, Pecile A (1984) Antinoci-
ceptive effect of centrally administered cimetidine and dimaprit
in the rat. Pharmacology 28:262–267
Patterson M, Murphy KG, le Roux CW, Ghatei MA, Bloom SR
(2005) Characterization of ghrelin-like immunoreactivity in
human plasma. J Clin Endocrinol Metab 90:2205–2211
Randall LO, Selitto JJ (1957) A method for measurement of analgesic
activity on inflamed tissue. Arch Int Pharmacodyn Ther 111:
409–419
Riediger T, Traebert M, Schmid HA, Scheel C, Lutz TA, Scharrer E
(2003) Site-specific effects of ghrelin on the neuronal activity in
the hypothalamic arcuate nucleus. Neurosci Lett 341:151–155
Seim I, Josh P, Cunningham P, Herington A, Chopin L (2011) Ghrelin
axis genes, peptides and receptors: recent findings and future
challenges. Mol Cell Endocrinol 340:3–9
Sibilia V, Lattuada N, Rapetti D, Pagani F, Vincenza D, Bulgarelli I,
Locatelli V, Guidobono F, Netti C (2006a) Ghrelin inhibits
inflammatory pain in rats: involvement of the opioid system.
Neuropharmacology 51:497–505
Sibilia V, Muccioli G, Deghenghi R, Pagani F, De Luca V, Rapetti D,
Locatelli V, Netti C (2006b) Evidence for a role of the GHS-R1a
receptors in ghrelin inhibition of gastric acid secretion in the rat.
J Neuroendocrinol 18:122–128
Taiwo YO, Coderre TJ, Levine JD (1989) The contribution of training
to sensitivity in the nociceptive paw-withdrawal test. Brain Res
487:148–151
Taub DD (2007) Novel connections between the neuroendocrine and
immune system: the ghrelin immunoregulatory network. Vita-
min Horm 77:325–326
Tucci SA, Rogers EK, Korbonits M, Kirkham TC (2004) The cannab-
inoid CB1 receptor antagonist SR141716 blocks the orexigenic
effects of intrahypothalamic ghrelin. Br J Pharmacol 143:520–523
van der Lely AJ, Tscho¨p M, Heiman ML, Ghigo E (2004) Biological,
physiological, pathophysiological, and pharmacological aspects
of ghrelin. Endocr Rev 25:426–457
Vergnano AM, Ferrini F, Salio C, Lossi L, Baratta M, Merighi A
(2008) The gastrointestinal hormone ghrelin modulates inhibi-
tory neurotransmission in deep laminae of mouse spinal cord
dorsal horn. Endocrinology 149:2306–2312
Winter CA, Risley EA, Nuss GW (1962) Carrageenin-induced edema
in hind paw of the rat as an assay for antiiflammatory drugs. Proc
Soc Exp Biol Med 111:544–547
Wu R, Dong W, Zhou M, Cui X, Hank Simms H, Wang P (2005)
Ghrelin improves tissue perfusion in severe sepsis via downreg-
ulation of endothelin-1. Cardiovasc Res 68:318–326
Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL (2008)
Identification of the acyltransferase that octanoylates ghrelin, an
appetite-stimulating peptide hormone. Cell 132:387–396
Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK (2006)
Expression of ghrelin receptor mRNA in the rat and the mouse
brain. J Comp Neurol 494:528–548
Pharmacological characterization of the ghrelin receptor 1759
123
